{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:39:49Z","timestamp":1786372789138,"version":"build-2736575974"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2017,7]]},"abstract":"\n Background and objectives<\/jats:title>\n Despite the high burden of CKD, few specific therapies are available that can halt disease progression. In animal models, clopidogrel has emerged as a potential therapy to preserve kidney function. The effect of clopidogrel on kidney function in humans has not been established.<\/jats:p>\n <\/jats:sec>\n \n Design, setting, participants, & measurements<\/jats:title>\n The Secondary Prevention of Small Subcortical Strokes Study randomized participants with prior lacunar stroke to treatment with aspirin or aspirin plus clopidogrel. We compared annual eGFR decline and incidence of rapid eGFR decline (\u226530% from baseline) using generalized estimating equations and interval-censored proportional hazards regression, respectively. We also stratified our analyses by baseline eGFR, systolic BP target, and time after randomization.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n At randomization, median age was 62 (interquartile range, 55\u201371) years old; 36% had a history of diabetes, 90% had hypertension, and the median eGFR was 81 (interquartile range, 65\u201394) ml\/min per 1 m\n 2<\/jats:sup>\n . Persons receiving aspirin plus clopidogrel had an average annual change in kidney function of \u22121.39 (95% confidence interval, \u22121.15 to \u22121.62) ml\/min per 1.73 m\n 2<\/jats:sup>\n per year compared with \u22121.52 (95% confidence interval, \u22121.30 to \u22121.74) ml\/min per 1.73 m\n 2<\/jats:sup>\n per year among persons receiving aspirin only (\n P<\/jats:italic>\n =0.42). Rapid kidney function decline occurred in 21% of participants receiving clopidogrel plus aspirin compared with 22% of participants receiving aspirin plus placebo (hazard ratio, 0.94; 95% confidence interval, 0.79 to 1.10;\n P<\/jats:italic>\n =0.42). Findings did not vary by baseline eGFR, time after randomization, or systolic BP target (all\n P<\/jats:italic>\n values for interaction were >0.3).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n We found no effect of clopidogrel added to aspirin compared with aspirin alone on kidney function decline among persons with prior lacunar stroke.<\/jats:p>\n <\/jats:sec>","DOI":"10.2215\/cjn.00100117","type":"journal-article","created":{"date-parts":[[2017,4,26]],"date-time":"2017-04-26T20:20:17Z","timestamp":1493238017000},"page":"1040-1047","source":"Crossref","is-referenced-by-count":2,"title":["Post Hoc Analyses of Randomized Clinical Trial for the Effect of Clopidogrel Added to Aspirin on Kidney Function"],"prefix":"10.2215","volume":"12","author":[{"given":"Jesse C.","family":"Ikeme","sequence":"first","affiliation":[{"name":"The Kidney Health Research Collaborative, University of California, San Francisco, California;"},{"name":"San Francisco Veterans Affairs Medical Center, San Francisco, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo E.","family":"Pergola","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center at San Antonio, San Antonio, Texas; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Scherzer","sequence":"additional","affiliation":[{"name":"The Kidney Health Research Collaborative, University of California, San Francisco, California;"},{"name":"San Francisco Veterans Affairs Medical Center, San Francisco, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Shlipak","sequence":"additional","affiliation":[{"name":"The Kidney Health Research Collaborative, University of California, San Francisco, California;"},{"name":"San Francisco Veterans Affairs Medical Center, San Francisco, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar R.","family":"Benavente","sequence":"additional","affiliation":[{"name":"University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen A.","family":"Peralta","sequence":"additional","affiliation":[{"name":"The Kidney Health Research Collaborative, University of California, San Francisco, California;"},{"name":"San Francisco Veterans Affairs Medical Center, San Francisco, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2017,4,26]]},"reference":[{"key":"B2-20230813","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0140-6736(13)60687-X","article-title":"Chronic kidney disease: Global dimension and perspectives.","volume":"382","author":"Jha","year":"2013","journal-title":"Lancet"},{"key":"B3-20230813","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/1358836X9800300312","article-title":"Clinical pharmacology of the adenosine diphosphate (ADP) receptor antagonist, clopidogrel.","volume":"3","author":"Schr\u00f6r","year":"1998","journal-title":"Vasc Med"},{"key":"B4-20230813","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ijcard.2008.12.091","article-title":"The reversible oral P2Y12 antagonist AZD6140 inhibits ADP-induced contractions in murine and human vasculature.","volume":"142","author":"H\u00f6gberg","year":"2010","journal-title":"Int J Cardiol"},{"key":"B5-20230813","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/01.ATV.0000142376.30582.ed","article-title":"ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels.","volume":"24","author":"Wihlborg","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B6-20230813","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1681\/ASN.2014010118","article-title":"P2Y12 receptor localizes in the renal collecting duct and its blockade augments arginine vasopressin action and alleviates nephrogenic diabetes insipidus.","volume":"26","author":"Zhang","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B7-20230813","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00395-009-0073-8","article-title":"Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes.","volume":"105","author":"Diehl","year":"2010","journal-title":"Basic Res Cardiol"},{"key":"B8-20230813","doi-asserted-by":"crossref","first-page":"ra55","DOI":"10.1126\/scisignal.2000588","article-title":"Autocrine purinergic receptor signaling is essential for macrophage chemotaxis.","volume":"3","author":"Kronlage","year":"2010","journal-title":"Sci Signal"},{"key":"B9-20230813","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1161\/01.HYP.19.5.464","article-title":"Renal injury from angiotensin II-mediated hypertension.","volume":"19","author":"Johnson","year":"1992","journal-title":"Hypertension"},{"key":"B10-20230813","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/ki.1994.230","article-title":"The glomerular response to injury: Progression or resolution?","volume":"45","author":"Johnson","year":"1994","journal-title":"Kidney Int"},{"key":"B11-20230813","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1159\/000190313","article-title":"Platelets in glomerular disease.","volume":"77","author":"Barnes","year":"1997","journal-title":"Nephron"},{"key":"B12-20230813","doi-asserted-by":"crossref","first-page":"F1238","DOI":"10.1152\/ajprenal.00535.2014","article-title":"Platelets are relevant mediators of renal injury induced by primary endothelial lesions.","volume":"308","author":"Schwarzenberger","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"B13-20230813","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.amjcard.2003.11.048","article-title":"Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention.","volume":"93","author":"Quinn","year":"2004","journal-title":"Am J Cardiol"},{"key":"B14-20230813","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1160\/TH13-11-0915","article-title":"Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors.","volume":"112","author":"Adamski","year":"2014","journal-title":"Thromb Haemost"},{"key":"B15-20230813","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.amjcard.2009.01.367","article-title":"Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting.","volume":"103","author":"Antonino","year":"2009","journal-title":"Am J Cardiol"},{"key":"B16-20230813","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1681\/ASN.2007020160","article-title":"Anti-inflammatory renoprotective effect of clopidogrel and irbesartan in chronic renal injury.","volume":"19","author":"Tu","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"B17-20230813","doi-asserted-by":"crossref","first-page":"F161","DOI":"10.1152\/ajprenal.00281.2007","article-title":"Purinergic receptors contribute to early mesangial cell transformation and renal vessel hypertrophy during angiotensin II-induced hypertension.","volume":"294","author":"Graciano","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"B18-20230813","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.atherosclerosis.2006.12.009","article-title":"A single loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: Results of a double-blind, randomized study.","volume":"196","author":"Warnholtz","year":"2008","journal-title":"Atherosclerosis"},{"key":"B19-20230813","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1042\/CS20090392","article-title":"Clopidogrel, independent of the vascular P2Y12 receptor, improves arterial function in small mesenteric arteries from AngII-hypertensive rats.","volume":"118","author":"Giachini","year":"2010","journal-title":"Clin Sci (Lond)"},{"key":"B20-20230813","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/j.2042-7158.2011.01313.x","article-title":"Endothelium-independent vasorelaxation by ticlopidine and clopidogrel in rat caudal artery.","volume":"63","author":"Froldi","year":"2011","journal-title":"J Pharm Pharmacol"},{"key":"B21-20230813","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1124\/jpet.110.178574","article-title":"Thienopyridines, but not elinogrel, result in off-target effects at the vessel wall that contribute to bleeding.","volume":"338","author":"Andr\u00e9","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"B22-20230813","doi-asserted-by":"crossref","first-page":"F619","DOI":"10.1152\/ajprenal.00444.2013","article-title":"Clopidogrel preserves whole kidney autoregulatory behavior in ANG II-induced hypertension.","volume":"306","author":"Osmond","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"B23-20230813","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1056\/NEJMoa1204133","article-title":"Effects of clopidogrel added to aspirin in patients with recent lacunar stroke.","volume":"367","author":"Benavente","year":"2012","journal-title":"N Engl J Med"},{"key":"B24-20230813","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1747-4949.2010.00573.x","article-title":"The secondary prevention of small subcortical strokes (SPS3) study.","volume":"6","author":"Benavente","year":"2011","journal-title":"Int J Stroke"},{"key":"B25-20230813","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","article-title":"GFR decline as an end point for clinical trials in CKD: A scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration.","volume":"64","author":"Levey","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"B26-20230813","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate.","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"B27-20230813","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/biomet\/73.1.13","article-title":"Longitudinal data analysis using generalized linear models.","volume":"73","author":"Liang","year":"1986","journal-title":"Biometrika"},{"key":"B28-20230813","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.0006-341X.2000.00779.x","article-title":"Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests.","volume":"56","author":"Robins","year":"2000","journal-title":"Biometrics"},{"key":"B29-20230813","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2307\/2530698","article-title":"A proportional hazards model for interval-censored failure time data.","volume":"42","author":"Finkelstein","year":"1986","journal-title":"Biometrics"},{"key":"B30-20230813","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1161\/CIRCULATIONAHA.115.019657","article-title":"Effect of intensive versus usual blood pressure control on kidney function among individuals with prior lacunar stroke: A post hoc analysis of the secondary prevention of small subcortical strokes (SPS3) randomized trial.","volume":"133","author":"Peralta","year":"2016","journal-title":"Circulation"},{"key":"B31-20230813","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1093\/ndt\/gft027","article-title":"Impaired platelet P2Y12 inhibition by thienopyridines in chronic kidney disease: Mechanisms, clinical relevance and pharmacological options.","volume":"28","author":"Morel","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"B32-20230813","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJMra020676","article-title":"Renal dysfunction complicating the treatment of hypertension.","volume":"347","author":"Palmer","year":"2002","journal-title":"N Engl J Med"},{"key":"B33-20230813","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa010323","article-title":"Acetaminophen, aspirin, and chronic renal failure.","volume":"345","author":"Fored","year":"2001","journal-title":"N Engl J Med"},{"key":"B34-20230813","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1093\/ndt\/gfn745","article-title":"Acetaminophen, aspirin and progression of advanced chronic kidney disease.","volume":"24","author":"Evans","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"B35-20230813","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0272-6386(03)00647-4","article-title":"Analgesic use and change in kidney function in apparently healthy men.","volume":"42","author":"Kurth","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"B36-20230813","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/archinte.164.14.1519","article-title":"Lifetime nonnarcotic analgesic use and decline in renal function in women.","volume":"164","author":"Curhan","year":"2004","journal-title":"Arch Intern Med"},{"key":"B37-20230813","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ijcard.2016.08.224","article-title":"Aspirin and renal insufficiency progression in patients with atrial fibrillation and chronic kidney disease.","volume":"223","author":"Pastori","year":"2016","journal-title":"Int J Cardiol"},{"key":"B38-20230813","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1056\/NEJM197702242960803","article-title":"Aspirin-induced depression of renal function.","volume":"296","author":"Kimberly","year":"1977","journal-title":"N Engl J Med"},{"key":"B39-20230813","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1111\/j.1538-7836.2011.04531.x","article-title":"Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity.","volume":"9","author":"Alexopoulos","year":"2011","journal-title":"J Thromb Haemost"},{"key":"B40-20230813","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.atherosclerosis.2014.01.017","article-title":"Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: A meta-analysis of randomized trials.","volume":"233","author":"Tang","year":"2014","journal-title":"Atherosclerosis"},{"key":"B41-20230813","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1681\/ASN.2014070721","article-title":"The dark side of extracellular ATP in kidney diseases.","volume":"26","author":"Solini","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B42-20230813","doi-asserted-by":"crossref","first-page":"154","DOI":"10.5414\/CN107325","article-title":"P2 purinoceptors: Renal pathophysiology and therapeutic potential.","volume":"78","author":"Booth","year":"2012","journal-title":"Clin Nephrol"},{"issue":"Suppl 1","key":"B43-20230813","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification.","volume":"39","year":"2002","journal-title":"Am J Kidney Dis"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201707000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:36:41Z","timestamp":1786369001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201707000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,26]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.00100117","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,26]]}}}